Agent or method for treating severe aphasia in cerebrovascular accident chronic stage
OwnerHideki Ohyamainventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating a patient having suffered from severe aphasia associated with cerebrovascular accident chronic stage for at least three years, wherein said treatment consists essentially of administering a composition comprising 2-oxo-1-pyrrolidineacetamide as an active ingredient and a pharmaceutically acceptable carrier.
Claims2
A method for treating a patient having had severe aphasia associated with cerebrovascular accident chronic stage for at least three years, which consists essentially of administering a therapeutically effective amount of a composition to said patient, wherein said composition comprises 2-oxo-1-pyrrolidineacetamide as an active ingredient and at least one pharmaceutically acceptable carrier, and wherein said patient has had severe aphasia associated with cerebrovascular accident chronic stage for at least three years.
A method for treating severe aphasia associated with cerebrovascular accident chronic stage, which comprises administering a composition comprising 2-oxo-1-pyrrolidineacetamide as an active ingredient and at least one pharmaceutically acceptable carrier to a patient diagnosed with severe aphasia associated with cerebrovascular accident chronic stage and with no expectation of improvement in symptoms after at least 3 years of language rehabilitation, and whereby 2-oxo-1-pyrrolidineacetamide is administered to said patient at a dose of from 9 g/day to 40 g/day, for at least 2 months.
Dependencies are inferred from the claim text.